Metsera
A clinical-stage biopharmaceutical company developing next generation medicines for obesity and metabolic diseases.
Founded in 2022 by Population Health Partners and ARCH Venture Partners, Metsera has raised $290 million in financing from leading healthcare investors and is based in New York City.
Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape.
Latest Metsera News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze